Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Marc Peeters, Salvatore Siena, Eric Van Cutsem, Alberto Sobrero, Alain Hendlisz, Stefano Cascinu, Haralabos Kalofonos, Giovanna Devercelli, Michael Wolf, Rafael G. Amado

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient- reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of pani- tumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorec- tal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. ST by modified National Cancer Institute CTCAE v3.0 and modified Dermatology Life Quality Index (mDLQI), health-related quality of life (HRQOL), and CRC symptoms were measured. ST was analyzed using a landmark approach. Associations by KRAS mutational status were also assessed. RESULTS: Of 463 patients, 208 of 231 (90%) panitumumab patients and 184 of 232 (79%) BSC patients had ≥1 postbaseline patient-reported outcome (PRO) assessment. Panitumumab patients with more severe ST had significantly longer overall survival (OS) (grade 2-4:grade 1; hazard ratio, 0.60; P =.0033). Lower mDLQI scores (

Original languageEnglish
Pages (from-to)1544-1554
Number of pages11
JournalCancer
Volume115
Issue number7
DOIs
Publication statusPublished - Apr 1 2009

Keywords

  • Colorectal cancer
  • Health-related quality of life
  • Panitumumab
  • Skin toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy'. Together they form a unique fingerprint.

Cite this